Hemophilia: Difference between revisions
From WikiLectures
(Original from wikiscripta : Hemofillie) |
(Original from wikiscripta : Hemophilia) |
||
| Line 1: | Line 1: | ||
__BEZOBSAHU__ | __BEZOBSAHU__ | ||
<noinclude> | <noinclude> | ||
{{Infobox - | {{Infobox - genetic disease | ||
| | | name = Hemophilia | ||
| | | image = XlinkRecessive.jpg | ||
| | | label = Gonosomal recessive inheritance | ||
| | | clinical picture = blood coagulation disorder | ||
| | | cause = no or insufficient production of coagulation factors | ||
| | | diagnosis = prenatal, postnatal | ||
| SLG = | | SLG = | ||
| incidence | | worldwide incidence = 1:160,000 | ||
| | | prognosis = | ||
| MKN-10 = [https://old.uzis.cz/cz/mkn/D65-D69.html#D66 D66.] | | MKN-10 = [https://old.uzis.cz/cz/mkn/D65-D69.html#D66 D66.] | ||
| MeSH ID = D025861 | | MeSH ID = D025861 | ||
| OMIM = | | OMIM = | ||
| | | orphan = | ||
| MedlinePlus = | | MedlinePlus = | ||
| Medscape = | | Medscape = | ||
}} | }} | ||
</noinclude> | </noinclude> | ||
''' | '''Hemophilia''' is a disease with [[gonosomal recessive inheritance]]manifested by a [[blood clotting disease|blood clotting]]. The essence of the disease is either no or insufficient production of coagulation factors VIII, IX or XI. | ||
[[Gen]] | [[Gen]]s for clotting factors VIII and IX are linked to the sex [[chromosome X|chromosome X]]. The disorder occurs mostly in males, males ([[karyotype]] 46,XY) are [[hemizygous]]i. Women (karyotype 46,XX) – [[heterozygotes]] are carriers, the disease is rarely manifested in them (effect of [[lyonization]]). Of course, the disease manifests itself in recessive [[homozygotes]] females. | ||
== | ==Types of hemophilia== | ||
We distinguish two basic forms of hemophilia. The inheritance and manifestations of both types are the same. There is also a third type of hemophilia with autosomal inheritance. | |||
*{{OMIM|306700| | *{{OMIM|306700|Hemophilia A}} – the cause is a lack of coagulation factor VIII or a reduction of its functional activity below 10%. This can occur, for example, as a result of mutations in the gene for F8C (location Xq28). [[Mutation]] includes deletion, inversion, insertion or point mutation. Incidence: 1/10,000 boys. | ||
*{{OMIM|306900| | *{{OMIM|306900|Hemophilia B}} – this is a lack or reduction in the functional activity of coagulation factor IX, which is caused by a mutation of the F9 gene (location Xq27.1-q27.2). Incidence: 1/70,000 boys. | ||
*{{OMIM|612416| | *{{OMIM|612416|Hemophilia C}} – caused by deficiency of coagulation factor XI (F11 gene, 4q35 location). Inheritance is [[autosomal recessive inheritance|autosomal recessive]]. | ||
== | ==Manifestations of the disease== | ||
* | *Spontaneous bleeding (eg. epistaxis) | ||
* | *bleeding after minor trauma (formation of ecchymoses, hematomas) | ||
* | *Bleeding usually does not stop after compression | ||
* | *bleeding into the joints = hemarthrosis (joints deformed, blood irritates the synovium * remodeling; tile appearance) | ||
* | *bleeding into the GIT (manifestation of melena), URO (hematuria) | ||
==Treatment== | |||
The basis of the treatment of hemophilia is the injection of a clotting factor concentrate, which is absent in the blood of people with hemophilia. For each patient, the treatment is individual, depending on the severity of the disease and the current level of the clotting factor in the blood. Injection application can be performed at home. | |||
In children with a severe form of hemophilia, prophylactic treatment is used, where the patient with hemophilia regularly applies a certain amount of clotting factor even when there are no signs of bleeding. Prophylactic treatment helps to prevent spontaneous bleeding and protects above all from permanent damage to the joints. The precipitation factor is usually applied 2x to 3x a week. | |||
'' | Spontaneous bleeding (bleeding episode) may occur in people with hemophilia who do not apply clotting factor regularly. This is most often manifested by severe pain in the affected joint. Then it is important to administer a dose of clotting factor as soon as possible to prevent permanent damage to the joint. That's why it's important to have clotting factor concentrate at home. The treatment of the bleeding episode continues in cooperation with the hematology center under the guidance of a specialist doctor. | ||
''Dose calculation: ''1 unit/kg will increase fVIII by 2% a fIX by 1% | |||
We also use as supportive therapy ''[[antifibrinolytics]]'' (against bleeding from the oral cavity), and also we use ''[[csw:Desmopresin|desmopressin]]''. | |||
<noinclude> | <noinclude> | ||
== | ==Links== | ||
=== | ===Related articles=== | ||
*[[ | *[[Hemostasis disorders]]: [[Hereditary coagulopathies]] • [[Acquired coagulopathies]] • [[bleeding conditions (pediatrics)]] • [[hemorrhagic diseases (pathology)]] | ||
*[[ | *[[Hemostasis]] • [[Hemocoagulation]] • [[Blood coagulation test]] • [[Bleeding test]] | ||
*[[X- | *[[X-linked inheritance]] | ||
=== | ===External links=== | ||
*http://www.hemofilici.cz/cs/o-hemofilii | *http://www.hemofilici.cz/cs/o-hemofilii | ||
*https://www.hemofilie.cz/ – stránky pro veřejnost i osoby s hemofilií | *https://www.hemofilie.cz/ – stránky pro veřejnost i osoby s hemofilií | ||
=== | ===References=== | ||
*{{ | *{{Cite | ||
| | | type = book | ||
| | | surname1 = Indrák | ||
| | | name1 = Karel | ||
| | | collective = ano | ||
| | | title = Hematology | ||
| | | subtitle = VII. Vnitřní lékařství | ||
| | | volume = 1 | ||
| | | year = 2006 | ||
| isbn = 80-7254-868-9 | | isbn = 80-7254-868-9 | ||
}} | }} | ||
| Line 83: | Line 84: | ||
</noinclude> | </noinclude> | ||
[[ | [[Category:Internal medicine]] | ||
[[ | [[Category:Hematology]] | ||
[[ | [[Category:Pathology]] | ||
[[ | [[Category:Genetics]] | ||
[[ | [[Category:Pathophysiology]] | ||
Revision as of 19:14, 22 January 2023
__BEZOBSAHU__
Template:Infobox - genetic disease
Hemophilia is a disease with gonosomal recessive inheritancemanifested by a blood clotting. The essence of the disease is either no or insufficient production of coagulation factors VIII, IX or XI.
Gens for clotting factors VIII and IX are linked to the sex chromosome X. The disorder occurs mostly in males, males (karyotype 46,XY) are hemizygousi. Women (karyotype 46,XX) – heterozygotes are carriers, the disease is rarely manifested in them (effect of lyonization). Of course, the disease manifests itself in recessive homozygotes females.
Types of hemophilia
We distinguish two basic forms of hemophilia. The inheritance and manifestations of both types are the same. There is also a third type of hemophilia with autosomal inheritance.
- Hemophilia A (OMIM 306700) – the cause is a lack of coagulation factor VIII or a reduction of its functional activity below 10%. This can occur, for example, as a result of mutations in the gene for F8C (location Xq28). Mutation includes deletion, inversion, insertion or point mutation. Incidence: 1/10,000 boys.
- Hemophilia B (OMIM 306900) – this is a lack or reduction in the functional activity of coagulation factor IX, which is caused by a mutation of the F9 gene (location Xq27.1-q27.2). Incidence: 1/70,000 boys.
- Hemophilia C (OMIM 612416) – caused by deficiency of coagulation factor XI (F11 gene, 4q35 location). Inheritance is autosomal recessive.
Manifestations of the disease
- Spontaneous bleeding (eg. epistaxis)
- bleeding after minor trauma (formation of ecchymoses, hematomas)
- Bleeding usually does not stop after compression
- bleeding into the joints = hemarthrosis (joints deformed, blood irritates the synovium * remodeling; tile appearance)
- bleeding into the GIT (manifestation of melena), URO (hematuria)
Treatment
The basis of the treatment of hemophilia is the injection of a clotting factor concentrate, which is absent in the blood of people with hemophilia. For each patient, the treatment is individual, depending on the severity of the disease and the current level of the clotting factor in the blood. Injection application can be performed at home.
In children with a severe form of hemophilia, prophylactic treatment is used, where the patient with hemophilia regularly applies a certain amount of clotting factor even when there are no signs of bleeding. Prophylactic treatment helps to prevent spontaneous bleeding and protects above all from permanent damage to the joints. The precipitation factor is usually applied 2x to 3x a week.
Spontaneous bleeding (bleeding episode) may occur in people with hemophilia who do not apply clotting factor regularly. This is most often manifested by severe pain in the affected joint. Then it is important to administer a dose of clotting factor as soon as possible to prevent permanent damage to the joint. That's why it's important to have clotting factor concentrate at home. The treatment of the bleeding episode continues in cooperation with the hematology center under the guidance of a specialist doctor.
Dose calculation: 1 unit/kg will increase fVIII by 2% a fIX by 1%
We also use as supportive therapy antifibrinolytics (against bleeding from the oral cavity), and also we use desmopressin.
Links
Related articles
- Hemostasis disorders: Hereditary coagulopathies • Acquired coagulopathies • bleeding conditions (pediatrics) • hemorrhagic diseases (pathology)
- Hemostasis • Hemocoagulation • Blood coagulation test • Bleeding test
- X-linked inheritance
External links
- http://www.hemofilici.cz/cs/o-hemofilii
- https://www.hemofilie.cz/ – stránky pro veřejnost i osoby s hemofilií
References
- Incomplete citation of publication. INDRÁK, Karel. Hematology : VII. Vnitřní lékařství. 2006. vol. 1. ISBN 80-7254-868-9.
